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Outpatient treatment of alcohol use
disorders among subjects 60+ years: design
of a randomized clinical trial conducted in
three countries (Elderly Study)
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Barbara Braun6, Claus Thorn Ekstrøm7, Alyssa Forcehimes8, Christine Lizarraga9, Theresa B. Moyers10
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Abstract
Background: The proportion of 60+ years with excessive alcohol intake varies in western countries between 6–16
% among men and 2–7 % among women. Specific events related to aging (e.g. loss of job, physical and mental
capacity, or spouse) may contribute to onset or continuation of alcohol use disorders (AUD). We present the
rationale and design of a multisite, multinational AUD treatment study for subjects aged 60+ years.
Methods/Design: 1,000 subjects seeking treatment for AUD according to DSM-5 in outpatient clinics in Denmark,
Germany, and New Mexico (USA) are invited to participate in a RCT. Participants are randomly assigned to four
sessions of Motivational Enhancement Treatment (MET) or to MET plus an add-on with eight sessions based on the
Community Reinforcement Approach (CRA), which include a new module targeting specific problems of older
adults. A series of assessment instruments is applied, including the Form-90, Alcohol Dependence Scale, Penn
Alcohol Craving Scale, Brief Symptom Inventory and WHO Quality of Life. Enrolment will be completed by April
2016 and data collection by April 2017.
The primary outcome is the proportion in each group who are abstinent or have a controlled use of alcohol six
months after treatment initiation. Controlled use is defined as maximum blood alcohol content not exceeding 0.05
% during the last month. Total abstinence is a secondary outcome, together with quality of life andcompliance
with treatment.
Discussion: The study will provide new knowledge about brief treatment of AUD for older subjects. As the
treatment is manualized and applied in routine treatment facilities, barriers for implementation in the health care
system are relatively low. Finally, as the study is being conducted in three different countries it will also provide
significant insight into the possible interaction of service system differences and related patient characteristics in
predictionof treatment outcome.
Trial registration: Clinical Trials.gov NCT02084173, March 7, 2014.
Keywords: Alcohol use disorder, 60+ years, Rrandomized clinical trial, Motivational Enhancement Therapy,
Community reinforcement approach
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Introduction
For several decades the prevention of adolescent high-
risk alcohol use and the treatment of middle aged pa-
tients with alcohol use disorders (AUD) have been major
public health targets. Less attention has been paid to the
development of AUD treatment programs that are tai-
lored to specific treatment needs of older adults (60+
years) with AUD. We report on the rationale and design
of a multi-centre treatment study conducted in
Denmark, Germany and USA for this age group.
Background
Prevalence
The proportion of older adults with problematic alcohol
consumption is of considerable size. In Denmark the
share of men aged 65 years and older drinking more
than the official Danish “high-risk” limit of 21 standard
drinks (1 standard drink = 12 g pure alcohol) per week
has declined from 13.8 % in 2010 to 11.7 % in 2013, with
a similar decline for women drinking above the “high-
risk” limit of 14 standard drinks per week from 8.2 % to
6.9 % [1]. However, proportions are high, and because of
the increasing number of people reaching a higher age
the absolute number is also increasing. In Germany the
percentage of men aged 60–64 years drinking at hazard-
ous level or above (>60 g pure alcohol per day) has been
reported to be 6.2 % and among women in the same age
group the percentage was 1.6 % (>40 g pure alcohol per
day) [2]. Among older adults in residential care facilities
14 % have a misuse of alcohol [3], and among patients
aged 75 years and older in general practice 6.5 % have
at-risk alcohol consumption [4]. In the USA among per-
sons aged 65 and older 16 % of men and 4 % of women
reported an unhealthy drinking pattern (monthly use ex-
ceeding 30 drinks or heavy episodic drinking of four or
more drinks in any single day during a typical month in
the previous year) [5]. In the National Survey on Drug
Use and Health 6.7 % of 65 years and older persons re-
ported alcohol abuse or alcohol dependence according
to DSM-IV, and among past-year alcohol users the pro-
portion was 15.4 % [6]. In this age group 13 % of men
and 8 % of women showed at-risk drinking, and 14 % of
men and 3 % of women binge drinking [7].
Age-related risk- factors and drinking motives
Older adults with a high level of alcohol consumption
constitute a heterogeneous group with different histories
of alcohol consumption. Some have started drinking ex-
cessively early in life and have survived into late adult-
hood continuing their level of alcohol consumption or
experiencing periods of recovery and exacerbation; some
have started drinking excessively during middle life, con-
tinuing their alcohol consumption which may become
more problematic with increasing age; and some have
started drinking excessively late in life. To our know-
ledge there are no data on the distribution of these dif-
ferent groups within older adults. Different causes for
late-onset drinking have been put forward: difficulty in
coping with loneliness, deteriorating social function, re-
tirement, depression, sadness, bereavement, hopeless-
ness, and others [8, 9]. Some may cope with losses and
loneliness by drinking [10].
Age-related negative alcohol use consequences
Light alcohol consumption has consistently been re-
ported to have a protective effect on cardiovascular ill-
ness as well as on mortality, including all-cause
mortality [11–13]. Alcohol may improve self-esteem,
provide relaxation, and is often, but certainly not always,
consumed socially [14]. However, AUD-related negative
consequences clearly outweigh these beneficial effects,
and the threshold for harmful effects becomes lower as
age increases. The psychosocial consequences of AUD
among the older adults may not be as severe as in youn-
ger subjects, as average severity of AUD is generally
lower compared to younger persons, and therefore be-
haviour is less affected by the alcohol consumption [4,
15]. Excessive alcohol intake in the older adults may in-
crease the risk of a number of conditions and diseases,
including hypertension [16, 17], hemorrhagic stroke
[12], diabetes mellitus [18], alcoholic liver disease and
other diseases in the gastrointestinal system, including
gastritis and ulcers with increased risk of bleeding, infec-
tious diseases [19], pulmonary diseases [20], and falls
with fractures as a consequence [21]. There is clear evi-
dence that in a dose-dependent pattern alcohol increases
the risk of cancer in many organs, including oropharynx,
larynx, oesophagus, liver, colon-rectum, and breast [22].
In addition, older adults may have physical and mental
co-morbidities that are treated with various medications,
introducing risk of harmful interactions between alcohol
and medication [23]. Further on, current data suggests
that AUD is associated with an increased risk of depres-
sion, [24]. Suicide is closely linked to depression and al-
cohol use. AUD may predispose to suicidal behaviour
through the increased risk of depression and promotion
of adverse life events [25]. Excessive alcohol intake may
be associated with increased risk of cognitive decline
and dementia [26], although data are conflicting.
Other studies on treatment of AUD have included
older adults, but the treatments have not been targeting
the older adults and rarely data specifically on this age
group are reported. As the western societies age rapidly
in the coming years older adults may be an increasing
challenge to treat. Given this background, we conduct a
randomized controlled clinical trial for subjects aged 60+
with DSM-5 AUD, with one standard and one age-
adapted brief intervention.
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Objectives
As an overall aim we strive to provide better treatment
for older people with AUD. As first objective we will
examine the effects of standard Motivational Enhance-
ment Therapy (MET), a very brief treatment based on
motivational interviewing. A Cochrane Review con-
cluded that MET was clearly more effective than no
treatment [27]. Since older individuals with AUD tend
to be psychosocially less affected by alcohol use, brief
treatment is seen at least as appropriate as it is for youn-
ger persons with alcohol problems [28]. Second, in order
to specifically address the needs of older adults, we will
examine whether an add-on to standard MET will pro-
duce greater improvement compared to MET alone. This
add-on is The Community Reinforcement Approach
(CRA) [29]. The CRA approach is based on the belief
that the surrounding environment can play a powerful
role in encouraging or discouraging alcohol use. Conse-
quently, it utilizes social, recreational, familial, and voca-
tional reinforcers to assist people in the recovery
process. The underlying perspective of CRA is relatively
simple: In order for a person to give up a significant re-
inforcer such as alcohol use, the alternative needs to be
more rewarding. Because old age is a period of transi-
tions with risk of or certainty of losses, for example re-
tirement and loss of friends and family members, we
have developed an additional module in CRA targeting
the specific needs older adults may encounter. Whether
or not drinking is a problem, the loss of sources of posi-
tive reinforcement may be a significant life transition as
people age, and a significant decrease in positive
reinforcement is a common precipitant of problem
drinking [30]. Thirdly, we analyse possible culture-
related differences of alcohol-related care, patient char-
acteristics and treatment outcome in the three States
participating, Denmark, Germany, and the USA. To our
knowledge, this is the first study of its kind: A study spe-
cifically targeting the treatment of older adults (60+
years) with alcohol problems and including 3 countries
across the Atlantic Ocean.
Methods
Design and settings
The study is conducted as a multicentre, multinational
single-blind randomized controlled study, with out-
patient alcohol treatment facilities in Denmark (3 sites),
Germany (10 sites), and USA (New Mexico) (1 site). We
started in spring 2014 and enrolment is expected to fin-
ish by April 2016. So far (August 2015) nearly 550 par-
ticipants have been enrolled.
In Denmark the municipalities offer alcohol treatment
in outpatient facilities. Treatment is free and is given to
all persons contacting the outpatient clinics. Patients can
be treated without a referral but can approach the clinics
directly. In Germany treatment is offered by a special-
ized addiction care system. Counseling and treatment is
free: the facilities receive city and State funds for out-
patient services. In New Mexico and Germany patients
over 60 years do not frequently seek treatment for addic-
tion in specialty care settings. However, in New Mexico,
they often see primary care providers, making primary
care settings particularly promising for the detection and
treatment of substance use disorders in older people in
the USA. Therefore, in Albuquerque the study is imple-
mented in a primary care clinic. In Germany, in addition
to outpatient counselling centers that belong to the ad-
diction care system, treatment is offered at the research
institution (Technische Universitaet Dresden) or an out-
patient psychotherapy clinic (Munich). In all three coun-
tries staff education is high and specialized training is
mandatory. Finally, in all three countries, detoxification,
if necessary, is offered before treatment.
Subjects
Based on a power calculation (see 2.6), we aim to recruit
1,000 patients, 500 in each of the two treatment arms.
Recruitment is primarily based on self-referral, including
referrals from general practice, hospitals etc., to the
treatment facilities. All patients aged 60 years or older
who ask for treatment are informed that this project is
being conducted and are recruiting participants. If a per-
son up front is not interested in the study this person re-
ceives standard treatment according to local guidelines.
If the person is interested, a session with a research as-
sistant is set up. The person (and family members or sig-
nificantly others if the person wants support or
discussing the implications of participating before decid-
ing) receives oral and written for information about the
study. There is no time limit for potential participants to
decide whether to participate or not, and the potential
participant may return to the research group with ques-
tions before deciding to participate or not. No project
procedures are conducted before a signed informed con-
sent, which may be revoked at any time if the participant
regrets participation. We strive for ecological validity
and only exclude patients who are unable to participate
in the therapy or are suffering from severe conditions
judged to threaten their safety or the validity of the
study. Inclusion criteria: (1) Older adults (≥60 years)
with an (2) alcohol use disorder according to DSM-5
[31] and (3) before participation pass 8 out of 10 ques-
tions in a comprehension quiz pertaining to the implica-
tions of participating in the study, for example
knowledge about voluntary participation and that any
acceptance of participation can be withdrawn at any
time. This custom-made quiz is conducted after in-
formed consent, and is in a multiple-choice format. Ex-
clusion criteria: (1) Current psychotic symptoms (2)
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Severe depression at the time of screening. (3) Manic
episode in the last three months prior to screening or
lifetime diagnosis of bipolar disorder. (4) Suicidal
thoughts/behaviour at the time of screening. (5) Use of
illicit opioids and/or illicit stimulants (all other forms of
medication is allowed, including opioids by prescription).
(6) Participating or having participated in other alcohol
treatment programs in the last 30 days at the time of
screening. Pure detoxifications are not exclusionary. (7)
Patients with legally authorized representatives.
Interventions
Brief MET treatment (Standard treatment)
Consists of 4 sessions, 1 per week. The intervention is
based on the initial phases of the Combined Behavioral
Intervention (CBI) from Project COMBINE [32, 33], and
includes motivational interviewing, a functional analysis
and planning for change as appropriate. In this condi-
tion, the change plan focuses exclusively on self-directed
activities both during the treatment and after the 4 ses-
sions are completed. A concerned significant other
(CSO) may participate in the last session.
Extended treatment
Consists of 4 initial sessions similar to those in the
Brief MET Treatment, except that the change plan is
explicitly designed to include therapeutic modules to
be completed collaboratively with the therapist. Simi-
larly to the Brief MET Treatment, a CSO can be in-
cluded in session 4. After the first 4 sessions, up to 8
additional sessions can be used by the therapist and
client to implement the change plan with 1 session
per week. This is accomplished through modules ad-
dressing specific areas pertaining to older age alcohol
use disorders, which are together called CRA for Se-
niors (CRAS-S). CRAS-S consists of 5 independent
modules: 1) Coping with Craving, Urges, and Social
Pressure to Drink; 2) Coping with Aging; 3) Mood
Management Training; 4) Building a Sober Network;
and 5) Social and Recreational Counselling. These
modules are based on the manual and procedures for
the Combined Behavioural Intervention (CBI) as de-
veloped and tested in the COMBINE trial. Unique to
this intervention, a module to manage the challenges
of aging has been developed. This module, Coping
with Aging, addresses older adults’ needs and prob-
lems with strategies for coping with aging and attend-
ant losses. Formulated to encompass the 5 domains
from the Happiness Form, the module on aging is
adapted to the style and procedures of CRA (Table 1).
Based on the change plan, the relevant topics/mod-
ules for treatment are chosen by participant and ther-
apist. Thus the manual consists of standardized
modules with detailed descriptions of the content and
procedures for each module, but flexibility to allow
the therapist and client to choose which modules are
relevant for patient’s problem profile. The selection
and order of modules and how many sessions devoted
to each module is planned collaboratively, and ses-
sions typically include more than one module at a
time.
Instruments and measurement
Patients will be assessed at screening, at baseline, at
the end of MET treatment (4 weeks after baseline), at
the end of MET + CRA treatment (12 weeks after
baseline), at six months after baseline (the time of
primary outcome), and at 12 months after baseline
(See Table 2).
Screening includes Modules J (alcohol), A (depression),
D (manic episode), and L (psychosis) of the Mini-
International Neuro-psychiatric Interview (M.I.N.I.) (ver-
sion 5.0.0) to assess inclusion and exclusion criteria [34].
To comply with the DSM-5 criteria for alcohol use dis-
order two questions on craving have been added in
module J of the M.I.N.I. [35].
Baseline assessment includes the remaining modules
in the M.I.N.I. and the BSI (Brief Symptom Inventory)
[36] in order to assess the current psychopathology
burden of the patient. The Charlson Comorbidity
Index is used to assess the patient’s physical status,
including a self-report of the patient’s current medica-
tion [37]. In addition to this, data on demographics
are collected: highest level of education, current work
situation (type of job, retired, unemployed, etc.), mari-
tal status, family and friends, type of housing, and
hobbies and interests, including out-of-house activ-
ities. Further, to examine the patient’s attitude to-
wards treatment in general, the patient is asked about
what he or she wants from treatment (e.g. abstinence
or controlled consumption). Weight and height is also
collected and used for the Blood Alcohol Content
(BAC) calculations.
Across baseline and follow-up assessments several
aspects of alcohol consumption are measured (see
Table 2): alcohol consumption (Form-90) [38], severity
of dependence (Alcohol Dependency Scale) [39], crav-
ing (Penn Alcohol Craving Scale [40] and Alcohol
Abstinence Self-Efficacy Scale [41]), and motivation
for change and treatment, the latter including therapy
compliance and treatment satisfaction (custom-made
questionnaires). Further, changes in quality of life
(WHOQOL-BREF) [42] and problems related to
aging, psychological and psychiatric problems are
assessed (Personal Happiness Form) [33].
At 6 months follow-up hair-samples are collected from
all participants.
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Table 1 Personal happiness form, adapted from the combine study [33]
Personal happiness form
How happy or satisfied are you with each of these areas of your life?
(circle only one number for each item)
If unsatisfied, (= < 5), what is the reason? Please
mark more than one if appropriate*
Life areas Completely
dissatisfied
Somewhat
dissatisfied
Somewhat
satisfied
Mostly
satisfied
Completely
satisfied
Doesn’t
apply
(IR)
Loss Loneliness Loss of
ability due to
aging
Something
else, please
note
Growing old* 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Inter personal relations
Relationship with
partner/spouse
1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Friends and social life 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Family relationships 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Love and affection 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Sex life 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Social life
Leisure time and fun 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Giving/caring for
others
1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Personal safety,
security
1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Life circumstances
Job/work/pension 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Where I live 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Money, financial
security
1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
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Outcome measures and hypotheses
Primary outcome
 Proportion of patients with abstinence or controlled
use (maximum alcohol resulting in an estimated
BAC ≤ 0.05 %) in the last 30 days at 6 months after
start of treatment.
Although “controlled use” is included as a positive out-
come in the primary outcome analysis, secondary ana-
lyses will examine total abstinence as a treatment
outcome. In the program, the therapist as a treatment
goal recommends abstinence. However, participants who
are unwilling to become abstinent are supported in
achieving a reduction of their alcohol use.
A priori hypotheses
1. Patients randomly assigned to a brief outpatient
behavior therapy program (MET; Treatment Group
1) will show a significant improvement of their
drinking pattern between onset, end of treatment
and 6- and 12-month follow-up.
2. Patients randomly assigned to a more intensive
outpatient behavior therapy (MET plus CRA;
treatment group 2) will show a significant greater
Table 1 Personal happiness form, adapted from the combine study [33] (Continued)
Physical health
Physical health 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Physical activities,
exercise
1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Daily routine, the
small tasks during
the day
1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Eating, weight 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Psychological health
Mood and self-
esteem
1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Stress and anxiety 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Anger and
arguments
1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Spirituality 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Memory 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
Mental ability 1 2 3 4 5 6 7 8 9 10 IR 0 = no 0 = no 0 = no
1 = yes 1 = yes 1 = yes
9 = irr. 9 = irr. 9 = irr.
*Added a question about aging in general and if dissatisfaction in any domain is reported, then is it because of factors related to aging
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improvement of their drinking pattern between
onset, end of treatment and 6- and 12-month
follow-up than treatment group 1. A clinically sig-
nificant difference in outcome is defined as at least a
10 %-points greater rate of abstinence or drinking in
a controlled manner in treatment group 2 compared
to group 1.
Secondary outcomes
 Proportion of total abstinence in each treatment
group at 6-month follow-up
 Percentage of patients with abstinence or controlled
use (maximum daily alcohol intake equivalent to
BAC ≤ 0.05 %):
(1)In the last 7 days before regular end of treatment
(end of MET and end of MET + CRA,
respectively)
(2)In the last 30 days at 12 month follow-up
 Quality of life
 The proportion of clients completing the planned
treatment
Statistical analyses
Multiple logistic regression models will be used to ana-
lyse primary and secondary outcomes, and explanatory
variables will include treatment, site, gender and age as
well as other relevant demographic variables. The statis-
tical analyses will be based on an “intent-to-treat”-ap-
proach, thus all patients randomized to treatment will
be included. A multiple imputation strategy will be used
in case of missing explanatory variables. The primary hy-
pothesis of differences between treatment conditions will
be tested one-sided since MET + CRA treatment is an
extension of MET treatment. All other hypotheses will
also be tested one-sided. In addition, we will perform a
participation analysis where a logistic regression analysis
is used to investigate how available demographics char-
acteristics affect the probability that an individual will
accept participation in the study.
Table 2 The evaluation instruments
Assessment Purpose/Content BL Wk
4
Wk
12
Wk
26
Wk
52
Alcohol consumption, dependence, and criteria for AUD
Form 90-AI/F [38] Primary outcome: daily alcohol use • • • • •
Alcohol Dependence Scale [39, 47] Alcohol Dependence • • •
Drinker Inventory of
Consequences [48]
Adverse consequences of drinking • • • • •
Mini-International Neuro-
psychiatric interview [34]
Module J: Assess whether the patient continuously
fulfil the DSM-5 criteria for AUD
• • • • •
Motivation
Importance, Confidence, Readiness
[49] (3 Likert scales)
Change in motivation • • • • •
Craving
Penn Alcohol Craving Scale [40] Changes in craving • • • • •
Alcohol Abstinence Self-Efficacy
Scale T/C [41]
Changes in self-efficacy • • • • •
Psychological and Psychiatric assessment
Brief Symptom Inventory 18 [36] Changes in anxiety, depression etc. • • • • •
Quality of life, domains with problems related to aging
WHOQOL-BREF [42] Changes in quality of life • • • • •
Personal Happiness Form [33] Identifying and assessing changes in interpersonal relations (family, friends, etc), life
circumstances (housing, work/retirement, etc.), physical and psychological health
• • • • •
Therapy Compliance and Treatment Satisfaction
Questionnaire on “Goal of
treatment”
Questions on what the patients wants from treatment •
Session Record Forma Quality control • • •
Treatment Satisfaction Form Patients’ evaluation of treatment • • • •
Hair sample of 10 % of patients Measuring alcohol to assess alcohol consumption the last 30 days •
BL: Baseline
Wk: week
aCompleted after every session during MET- and CRA-treatment, week 1–12
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The primary outcome is abstinence or controlled use
as stated above. Information from the Form-90 is used
to calculate the BAC based on the Widmark formula
with an age adjustment [43].
Power calculation
The number of patients is based on a power calculation
with an expectation that at least 50 % of patients in
MET treatment and 60 % of patients in the MET + CRA
will have a good clinical outcome six months after treat-
ment initiation as defined above in primary outcome.
Since MET + CRA is an extension of MET, we will em-
ploy 1-sided hypothesis testing. With a significance level
of 5 % (one-sided) and a power of 90 % each treatment
group, MET and MET + CRA, will require 423 patients.
As we foresee a dropout rate at approximately 15 %, we
will strive for 500 patients in each group.
Quality assurance and fidelity monitoring
Several procedures are employed to ensure and docu-
ment fidelity of the two study treatments.
All therapists are trained in both treatments. The ther-
apists are assigned before randomisation and must
therefore be able to deliver both. As 3 different countries
and 16 sites participate, the training program has two
steps: First, a minimum of 2 therapists from each sites
participated in a “train-the-trainers” – conference in
Denmark. At this 5-day conference the therapists were
introduced to the therapies and trained extensively.
These trained therapists subsequently train all other par-
ticipating therapists locally at each site. Therapy sessions
are digitally audio-recorded. Local supervisors at each
site, experienced in the treatment and in supervision,
continuously review randomly drawn sessions from each
therapist and give feedback to therapists to ensure con-
cordance with the treatment manuals. On-going supervi-
sion includes biweekly Skype meetings between all local
supervisors and the overall supervisors on the treatment
delivery in order to discuss and synchronize treatment
delivery across sites, and secure treatment manual
adherence.
Treatment fidelity monitoring is based on digital re-
cordings of all sessions performed in the study. A ran-
dom sample equivalent to 10 % of all sessions is drawn
and scored by independent coders using the method-
ology of MITI 4 (Motivational Interviewing Treatment
Integrity) [44] to measure fidelity to the style of the ther-
apy. In addition, the coders complete a checklist of the
content in the sessions.
Data collection is performed by research assistants (in-
terviewers) not involved in the treatment and blinded to
treatment assignment. Data collection is based on man-
ualized procedures, and data are directly entered into
the database through iPads or computers. The data
forms are programmed with logical rules and allowed
values, thus assisting the interviewer during the process.
Data quality and completeness is continuously moni-
tored. Twenty percent of the air samples are randomly
selected for analysis to validate the self-reported data.
Ethical approval
The study is approved by the ethical committee systems
following the local rules and regulations for participating
in scientific research project in all 3 countries: In
Denmark by The Regional Scientific Ethical Committees
for Southern Denmark, project-ID S-2013138; Germany,
project-ID EK 389102013 (the ethics committee, Tech-
nische Universitäet, Dresden) and Ethical Board of the
German Society of Psychology (DGPs, Reg.-No. EK-
Antrag Pfeiffer-Gerschel / Bühringer 12/2013, Munich);
and USA, New Mexico, project-ID University of New
Mexico HRRC #13-580. The study is also registered in
the Clinical Trials gov database: NCT02084173.
Organisation, administration, and oversight
The Principal Investigator (PI) of each country together
with the director of the RESCueH program (a research
program consisting of five Danish alcohol treatment
studies: Relay Study, Elderly Study, Self-match Study,
Cue Exposure Study, and Healthy Lifestyle Study) forms
the principal decision-making body of the study (Steer-
ing Committee, SC). They oversee all aspects of the de-
sign, execution, and publication of the study. The SC
has designated subcommittees to develop and monitor
aspects of the study. Each of these subcommittees refers
directly to the director, which brings issues/recommen-
dations to the SC’s attention for discussion and deci-
sion/approval. Logistically, fortnightly Skype meetings
are held in which all PIs and the director, including rele-
vant members of the staff, participate. The subcommit-
tees also meet via Skype at regular intervals to discuss
issues pertaining to their area of responsibility.
The official study language is English. Manuals and all
other study material are originally written in English and
only patient-related material is translated into Danish,
German and Spanish.
To manage revisions of protocol and treatment man-
uals, as well as securing that all study sites have access
to the same versions of the different instruments and
questionnaires, Microsoft’s SharePoint is used. The
SharePoint, which is supervised by the SC, is also used
for storing minutes from the different Skype meetings,
as well as all other decisions made so everybody in the
study has instant access to all relevant information.
The SC organizes data management in collaboration
with OPEN (Odense Patient data Explorative Network)
[45], which provides the infrastructure for data entry
and databases. All data entry and databases are based on
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REDCap™ (Research Electronic Data Capture), which is a
secure web application for building and managing online
data entry systems [46]. Thus all data collection is based
on directly entering interview data into the databases
through iPads or computers. The REDCap instrument
assists the interviewer by build-in security warnings, e.g.
alerts if a value not allowed is entered. OPEN and RED-
Cap also provide “in real time” monitoring of for ex-
ample recruitment rates, which are distributed to all
participating staffs in weekly newsletters. The newslet-
ters are also used as communication of decisions made
by the SC.
Finally, the SC meets once a year with an international
Advisory board consisting of Emeritus Distinguished
Professor William R. Miller, New Mexico, USA, Emeritus
Professor Gerard Schippers, The Netherlands, Dr. Gillian
Tober, United Kingdom, as well as representatives from
the Lundbeck Foundation, the University of Southern
Denmark, the Region of Southern Denmark, and The
Municipality of Odense. The Dean of the Faculty of
Health Sciences, University of Southern Denmark is chair-
man of the advisory board.
Pilot study
From January 2014 to April 2014 pilot testing all the in-
struments and the logistics involved in the study was
conducted. A total of 89 patients participated, and based
on the experience we added The Brief Symptom Inven-
tory (BSI) to evaluate psychological and psychiatric
problems in more detail [36]. No other major changes
were found necessary.
Expected results
This study will present knowledge about brief treatment
of AUD for older subjects, including knowledge about
the effects of a brief intervention and the effects of
targeting treatment to specific needs. The comprehen-
sive assessment program will also gain insight into the
characteristics of older adults seeking treatment, which
may contribute to further refinement of treatment and
prevention of AUD among older adults. In addition, the
interventions are manualized and being tested under
“real world” conditions in three different countries, so
they could be implemented relatively easily in western
countries if proven effective. As we have aimed for as
few exclusion criteria as possible we believe the study
will show effectiveness and not solely efficacy. This will
be very useful when planning future treatments both for
therapists and for organisers of health care services.
Discussion
Challenges
As the study is conducted in different countries with dif-
ferent treatment cultures and organisation of the health
care system it is not possible to define a “treatment as
usual (TAU)” across all countries. Therefore we have de-
cided not to compare any of the treatment groups with a
control group based on TAU. Based on experience from
daily clinical work we have decided that a meaningful
outcome is a success rate of at least 50 % and, if extra
effort (the extended CRA modules) is worth pursuing,
this shall gain at least 10 % higher success rate.
In that line of thinking, we have also discussed a clin-
ical relevant outcome. We aim for abstinence, but, as
some patients prefer “controlled use”, and reduction of
alcohol use can be a relevant factor in terms of harm re-
duction, we have decided to define a success as abstin-
ence or controlled use (maximum daily alcohol intake
equivalent to BAC ≤ 0.05 %) in the last 30 days at 6
months after start of treatment.
Innovative aspects
The present study will gain new insights into older
adults seeking treatment for their alcohol misuse. This
has only been the focus of a small number of studies so
far. Not only will new data be available, but simultan-
eously from different countries and cultures across the
Atlantic Ocean. This will add to the generalizability of
the results or provide information about the cross-
cultural differences in treatment effects. If the treatment
offered is successful the study will also show that a brief
intervention is feasible and is easy to implement for this
age group. In addition, as the design is an add-on design,
the study will gain information about whether a very
brief intervention focusing on motivation and planning
for change is sufficient or including modules dedicated
to help the patient execute these changes achieve better
outcomes. In addition, information on patient character-
istics that predict better results in both treatment condi-
tions will help to improve assignment of brief
interventions to elderly subjects with AUD. Further, as a
module in the adapted CRA is dedicated to the needs of
older adults this will provide knowledge about whether
such a target is relevant or not. Finally, the study will
provide data on the use of hair samples when assessing
alcohol use.
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